Table 1.
Characteristics of participants by aPL status at study baseline*
| DATA | aPL positivity on any measure n=197 |
aPL negativity on all measures n=759 |
Combined n=956 |
|---|---|---|---|
| DEMOGRAPHIC | |||
| Age at baseline, years (SD) | 81.4 (6.3) | 81.1 (7.3) | 81.1 (7.1) |
| Women, n (%) | 140 (71.1%) | 548 (72.2%) | 688 (72.0%) |
| Education, years (SD) | 15.2 (3.3) | 15.3 (3.1) | 15.3 (3.2) |
| COGNITIVE** | |||
| Global cognitive function score | −0.1 (0.7) | 0.0 (0.6) | 0 (0.6) |
| Perceptual speed score | −0.3 (0.9) | −0.1 (0.9) | −0.1 (0.9) |
| Working memory score | −0.1 (0.7) | 0.1 (0.8) | 0.1 (0.7) |
| Episodic memory score | −0.1 (0.9) | 0.0 (0.8) | 0.0 (0.8) |
| Semantic memory score | −0.1 (0.8) | 0.0 (0.7) | 0.0 (0.7) |
| Visuospatial ability score | 0.0 (0.9) | 0.1 (0.8) | 0.1 (0.8) |
| MOTOR** | |||
| Global parkinsonian signs score | 2.9 (1.5) | 2.7 (1.4) | 2.7 (1.5) |
| Gait disturbance score | 4.2 (2.3) | 3.6 (2.2) | 3.7 (2.3) |
| Bradykinesia score | 2.8 (2.2) | 2.5 (2.2) | 2.6 (2.2) |
| Rigidity score | 1.2 (2.0) | 1.1 (1.8) | 1.1 (1.8) |
| Tremor score | 1.0 (1.5) | 1.0 (1.4) | 1.0 (1.4) |
| Global motor score | 0.9 (0.2) | 1.0 (0.3) | 1.0 (0.3) |
| LABORATORY | |||
| C-reactive protein | 3610.3 (5314.4) | 4573.7 (7309.8) | 4409.0 (7013.5) |
| Matrix metalloproteinases (ratio) | 1.9 (25.6) | −26.6 (462.0) | −21.8 (420.9) |
| NEUROIMAGING | |||
| White matter hyperintensity score | −0.3 (0.4) | −0.3 (0.4) | −0.3 (0.4) |
| Any infarct, n (%) | 13/56 (23%) | 75/274 (27%) | 88/300 (27%) |
| NEUROPATHOLOGIC | |||
| Any brain infarct present,*** n (%) | 65 (48%) | 237 (52%) | 302 (51%) |
| Gross infarct present, n (%) | 49 (36%) | 168 (37%) | 217 (36%) |
| Microinfarct present, n (%) | 39 (29%) | 145 (32%) | 184 (31%) |
| Cortical, n (%) | 37 (26%) | 138 (29%) | 175 (28%) |
| Subcortical, n (%) | 48 (34%) | 174 (36%) | 222 (36%) |
| Vessel pathology**** | |||
| Atherosclerosis, n (%) | 53 (38%) | 175 (36%) | 228 (37%) |
| Arteriosclerosis, n (%) | 47 (33%) | 162 (34%) | 209 (34%) |
*
Mean (SD) at time of first aPL measure, unless otherwise specified; aPL positivity defined as positivity on any of the 6 blood measures at baseline (IgG and IgM for each of the 3 aPL)
**
At study baseline
***
Any infarct refers to infarcts of any size (gross or microscopic) and location (cortical or subcortical)
****
Grade of moderate-to-severe